vigabatrin has been researched along with Glaucoma in 3 studies
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Four subjects with advanced visual field loss of various origin (retinitis pigmentosa, vigabatrin-associated visual field defect, glaucomatous nerve fibre layer defect, and postgeniculate visual pathway defect) participated in this study." | 3.71 | [Evaluation of extensive visual field defects with computer-assisted kinetic perimetry]. ( Besch, D; Dietrich, TJ; Paetzold, J; Schiefer, U; Schiller, J; Vonthein, R, 2001) |
| "Vigabatrin (VGB) is an anti-epileptic medication which has been linked to peripheral constriction of the visual field." | 1.40 | Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin? ( Conway, ML; Cubbidge, RP; Hosking, SL; Zhu, H, 2014) |
| " Similarly, we showed that RGC degeneration can be induced by pharmacologically blocking the taurine-transporter with the chronic administration of a selective inhibitor, which results in a decrease in the taurine levels both in the plasma and in the retinal tissue." | 1.39 | Taurine is a crucial factor to preserve retinal ganglion cell survival. ( Cadetti, L; Degardin, J; Dubus, E; Forster, V; Froger, N; Gaucher, D; Ivkovic, I; Jammoul, F; Lorach, H; Pain, D; Picaud, S; Sahel, JA; Simonutti, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conway, ML | 1 |
| Hosking, SL | 1 |
| Zhu, H | 1 |
| Cubbidge, RP | 1 |
| Froger, N | 1 |
| Jammoul, F | 1 |
| Gaucher, D | 1 |
| Cadetti, L | 1 |
| Lorach, H | 1 |
| Degardin, J | 1 |
| Pain, D | 1 |
| Dubus, E | 1 |
| Forster, V | 1 |
| Ivkovic, I | 1 |
| Simonutti, M | 1 |
| Sahel, JA | 1 |
| Picaud, S | 1 |
| Schiefer, U | 1 |
| Schiller, J | 1 |
| Paetzold, J | 1 |
| Dietrich, TJ | 1 |
| Vonthein, R | 1 |
| Besch, D | 1 |
3 other studies available for vigabatrin and Glaucoma
| Article | Year |
|---|---|
Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?
Topics: Adolescent; Adult; Algorithms; Anticonvulsants; Female; Glaucoma; Humans; Male; Middle Aged; Sensiti | 2014 |
Taurine is a crucial factor to preserve retinal ganglion cell survival.
Topics: Animals; Cell Survival; Disease Models, Animal; Glaucoma; Membrane Glycoproteins; Membrane Transport | 2013 |
[Evaluation of extensive visual field defects with computer-assisted kinetic perimetry].
Topics: Adult; Brain Neoplasms; Diagnosis, Computer-Assisted; Female; Glaucoma; Hemangioma; Humans; Male; Mi | 2001 |